Statistical and practical considerations for clinical evaluation of predictive biomarkers. - Wikidata - wikimedia - TriplyDB

Statistical and practical considerations for clinical evaluation of predictive biomarkers.

Statistical and practical considerations for clinical evaluation of predictive biomarkers.

http://www.wikidata.org/entity/Q37463622

about

Biomarker-Guided Adaptive Trial Designs in Phase II and Phase III: A Methodological Review Predictive biomarkers for treatment selection: statistical considerations Consensus report of a joint NCI thoracic malignancies steering committee: FDA workshop on strategies for integrating biomarkers into clinical development of new therapies for lung cancer leading to the inception of "master protocols" in lung cancer Clinical Translation and Validation of a Predictive Biomarker for Patritumab, an Anti-human Epidermal Growth Factor Receptor 3 (HER3) Monoclonal Antibody, in Patients With Advanced Non-small Cell Lung Cancer.Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Imaging biomarker roadmap for cancer studies Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Overview of a chemoresponse assay in ovarian cancer Molecularly targeted therapies in non-small-cell lung cancer annual update 2014 Machine learning applications in cancer prognosis and prediction National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2014 Biomarker Working Group Report.Development of omics-based clinical tests for prognosis and therapy selection: the challenge of achieving statistical robustness and clinical utility.The Fundamental Difficulty With Evaluating the Accuracy of Biomarkers for Guiding Treatment Next-Generation Sequencing to Guide Clinical Trials.Automated fluorescent miscroscopic image analysis of PTBP1 expression in glioma.Biomarker kinetics in the prediction of VAP diagnosis: results from the BioVAP study.Planning clinically relevant biomarker validation studies using the "number needed to treat" concept.Low Ki67/high ATM protein expression in malignant tumors predicts favorable prognosis in a retrospective study of early stage hormone receptor positive breast cancer.Biomarker-Guided Non-Adaptive Trial Designs in Phase II and Phase III: A Methodological Review.Precision medicine for prostate cancer.Power estimation in biomarker studies where events are already observed.Prospective Validation of Diagnostic Tumor Biomarkers in Men Treated With Radiotherapy for Prostate Cancer.Targeting the folate receptor: diagnostic and therapeutic approaches to personalize cancer treatments.Measuring differential treatment benefit across marker specific subgroups: The choice of outcome scale.Statistical controversies in clinical research: basket trials, umbrella trials, and other master protocols: a review and examples.Beyond Correlations, Sensitivities, and Specificities: A Roadmap for Demonstrating Utility of Advanced Imaging in Oncology Treatment and Clinical Trial Design.Issues in developing multivariable molecular signatures for guiding clinical care decisions.The Challenge for Development of Valuable Immuno-oncology Biomarkers.Penalized regression for interval-censored times of disease progression: Selection of HLA markers in psoriatic arthritis.Quantitative assessment of a prognostic or predictive biomarker panel.Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology.On Enrichment Strategies for Biomarker Stratified Clinical Trials.A simulation study on estimating biomarker-treatment interaction effects in randomized trials with prognostic variables.

P2860

Q26766584-68E65EB3-91D5-41F2-92F8-EF1397E23AFA Q26778367-5DDD62D3-E6D4-43DF-BE22-03F71A998C2B Q26865266-3AB3B8F4-E14F-4125-8FE9-B62E11CE785C Q27853182-78D58195-E9B7-4BFD-A28D-FCD4DA3162E3 Q28079118-CB7825BF-5A08-4CFB-B21A-E7B1E0FD0168 Q30242020-20E60F1E-3A7B-474D-B925-19009614B00D Q33817285-9FC4FE2E-2A90-42DB-B8C1-310BC76C1D51 Q34071625-0992EA3F-95FF-4B81-B21C-00DAC88FCF57 Q35136424-F7377547-3D13-419E-82BC-A292F7C3FF68 Q35143671-EEB33616-FF3B-4104-B50C-E85D8DF07A2B Q35533376-D594CDC2-0600-4C82-BA23-C55E9E7F84F1 Q35538902-ECCC2E99-A1D6-433C-8AEE-A4A54BCCBD78 Q36173510-54A06474-7E34-4F76-9D15-0824E87996A7 Q36174832-F1F5C2BD-A69C-4376-84CE-D8439FDDD9A2 Q36304131-71A40CFA-925B-496E-989B-812AFF22F3E6 Q36795684-067ADE0F-3253-4FBC-8102-CCE9FED9ECF2 Q36871429-5405AB87-7BC5-45C0-BE30-C57DE9943930 Q37699132-34426745-D9C6-4D46-B0BC-D7849A4BC7C6 Q37731264-0B882505-7F81-4401-99A0-6E9C0990FF2C Q38263711-7B681A1A-33E7-4A7A-87E5-E31F86362A85 Q38372569-B7A6FA2D-287B-4067-B0EE-09FE0A45EE05 Q38375214-041B4A24-BD3A-45E2-8EFE-9A74AB85DF49 Q38524502-72DBE213-911C-4B4A-8ECC-043C7679D37B Q38932579-79219424-F3E6-416B-BA2F-5D2A24D6C51A Q39126105-87C02FEB-3CA7-4A2F-8587-5DC6729B415B Q39272347-0E9E9FE1-CF43-4685-BEFB-E3C13F6CC225 Q39454048-3A72E0D9-05BE-46E0-8598-2D0DF18464E9 Q46008297-4BEBA2ED-2EAB-4352-9F8E-F8A6E86B9D37 Q47667962-F95A12B4-DCB6-460C-AC82-078BA163DD83 Q47691525-E114BAA9-F61C-44A6-AB2C-2F235FB3BEE5 Q48353102-A184116C-439F-4A78-8CB3-18B222066E9B Q48654563-6DFD314F-6A50-412E-9A28-54F26EBEDCBB Q49795733-30078CD3-AC5E-497E-A65C-04DF5F5C97FE

P2860

Statistical and practical considerations for clinical evaluation of predictive biomarkers.

http://www.wikidata.org/entity/Q37463622

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 17 October 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Statistical and practical cons ...... tion of predictive biomarkers.

@en

Statistical and practical cons ...... tion of predictive biomarkers.

@nl

type

label

Statistical and practical cons ...... tion of predictive biomarkers.

@en

Statistical and practical cons ...... tion of predictive biomarkers.

@nl

prefLabel

Statistical and practical cons ...... tion of predictive biomarkers.

@en

Statistical and practical cons ...... tion of predictive biomarkers.

@nl

P1433

Q37463622-7789DFAA-9043-4F43-AA20-B88CEB28C95C

P1476

Q37463622-427D31C0-8956-4B62-976F-7EC581439A24

P2093

Q37463622-1D3FCED6-8692-4348-8200-F4CF57BC223E

Q37463622-329E540F-8088-4970-BBE2-D586234E7A95

Q37463622-5CB63495-C88A-4264-802D-3066AAAEC4FB

Q37463622-A51308CD-9F58-4009-BDC4-C6D3DD620592

Q37463622-FB4482DD-B557-4692-8636-F2A6EB6B8F03

P2860

Q37463622-04078317-322C-46DA-9CEA-F7927FF479DF

Q37463622-04D012BD-48D7-43B7-BD43-4CF75C361786

Q37463622-2CCB09E8-0FD4-4AB7-8CA3-6EFEBC65466F

Q37463622-2E91F6EC-7FE1-4F09-B965-05E68A6ACE55

Q37463622-3925E8B9-C461-47F9-9675-18471B9D07F4

Q37463622-3B018AC0-6D77-494C-8B43-867D38D1F48B

Q37463622-3EA599C3-23FE-448C-99F4-BF306703CF23

Q37463622-41A94DA5-D23D-45FB-BB85-79C9FBDBB4F7

Q37463622-4473909F-AEC5-46F6-A7C9-F94B8BC24D83

Q37463622-57E37116-FE0F-494E-B2F9-9DF6079704AF

P304

Q37463622-7D2A07BC-D9A8-4035-80B4-D0BEE397C4F3

P31

Q37463622-2C0AB7A4-6EFC-4B45-BA35-0AAC3557695D

P356

Q37463622-9E7CAFDF-8B44-4230-9034-CC715A9A669B

P407

Q37463622-C86D63F8-1062-405B-B693-88E4F6F56813

P433

Q37463622-2DF11AA4-116B-4160-A449-1BFD4AEF50A3

P478

Q37463622-CB679C08-E764-4933-9E22-4EA5E79B5928

P50

Q37463622-715B77ED-09E6-46C8-BDBD-90676DC2A97D

P577

Q37463622-42563340-7E43-4951-BDF1-0AC5D1E232F9

P5875

Q37463622-BA0A7F51-EEC6-4082-A456-D5B87208181B

P698

Q37463622-ECBE3DF3-4CF3-4FE5-B903-EDB52DCA7039

P921

Q37463622-A8DAA9DB-C78B-4AD0-845A-454D75A85E1F

Q37463622-B1F02210-3497-42F7-AB1B-A13323D9498A

P932

Q37463622-536E1BCF-98B1-4E4C-A562-EADB8A95A453

P356

P1433

Journal of the National Cancer Institute

P1476

Statistical and practical cons ...... tion of predictive biomarkers.

@en

P2093

Barbara A Conley

http://www.w3.org/2001/XMLSchema#string

Edward L Korn

http://www.w3.org/2001/XMLSchema#string

Jeffrey S Abrams

http://www.w3.org/2001/XMLSchema#string

Lisa M McShane

http://www.w3.org/2001/XMLSchema#string

Mei-Yin C Polley

http://www.w3.org/2001/XMLSchema#string

P2860

MGMT gene silencing and benefit from temozolomide in glioblastoma.

EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study.

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

Randomized clinical trials with biomarkers: design issues.

Use of archived specimens in evaluation of prognostic and predictive biomarkers

Biospecimen reporting for improved study quality (BRISQ)

The Influence of Low and Moderate Carotid Stenosis on Neurophysiologic Status of Patients Undergoing on-pump Coronary Artery Bypass Grafting.

Uses and abuses of tumor markers in the diagnosis, monitoring, and treatment of primary and metastatic breast cancer.

P304

1677-1683

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JNCI/DJT282

http://www.w3.org/2001/XMLSchema#string

P407

P433

22

http://www.w3.org/2001/XMLSchema#string

P478

105

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-10-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

258056531

http://www.w3.org/2001/XMLSchema#string

P698

24136891

http://www.w3.org/2001/XMLSchema#string

P921

P932

3888208

http://www.w3.org/2001/XMLSchema#string